Indica Labs and Lunit have announced an agreement to offer a fully interoperable solution, integrating Indica Labs’ HALO AP image management software platform with Lunit’s suite of AI-powered pathology products.

Lunit SCOPE PD-L1 NSCLC (non-small cell lung cancer) can be activated in the HALO AP user interface.

Analysis progress, all results and visual markup images can be reviewed in HALO AP, so users never have to leave the viewer or shift between systems.

With HALO AP’s built-in workflow management tools, an algorithm can automatically run upon slide intake so that the results are ready for the pathologist to review the case.

By integrating Lunit’s powerful AI solutions into HALO AP, pathologists, and researchers can benefit from the combined capabilities of both platforms, providing them with advanced tools to help them make more informed decisions.

The combined solution is already in use at Guardant Health.

“Leveraging the power of digital pathology and artificial intelligence to improve tissue-based research and patient care is at the core of our mission,” Indica Labs CEO and Founder Steven Hashagen said. “This valued collaboration enables us to seamlessly integrate Lunit’s AI pathology solutions, including Lunit SCOPE PD-L1 for non-small cell lung cancer (NSCLC), into HALO AP, our CE-IVD certified clinical image management platform.”

Lunit CEO Suh Beom-suk also said, “The partnership with Indica Labs, a market leader in digital pathology, with interoperable workflow integration, will enable pathologists and labs to deliver faster, more accurate, and more reproducible answers using Lunit’s AI solutions.”

Lunit SCOPE PD-L1 NSCLC is a CE-marked AI solution for detecting and analyzing PD-L1 TPS, a cancer biomarker. The solution may assist pathologists by minimizing interpretation variability and allowing better prediction of treatment outcomes for NSCLC patients, as demonstrated in study findings published in the European Journal of Cancer.

Indica Labs developed the HALO AP platform specifically to meet the needs of anatomic pathology labs worldwide.

The CE-IVD-certified HALO AP platform supports a wide range of tissue-based workflows, including primary diagnosis, secondary consults, clinical trials, synoptic reporting, quantitative analytics, and AI.

One of the key advantages of HALO AP is the seamless integration of AI solutions into the workflow, whether developed by Indica Labs or third parties.

To simplify integration, a HALO AP software development kit (SDK) is available to all algorithm developers. With HALO AP, users can utilize algorithms in an automated, stepwise workflow that can be locked, secured, and audited to prevent tampering or misuse.